HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RDNT
RadNet, Inc.
RDNT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RDNT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
RDNT's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RDNT PE Valuation
RDNT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RDNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
RDNT has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over RDNT on earnings, with more consistent year-over-year improvement.
RDNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | — |
| Q3 2026 | -$0.28 | -$0.11 |
| Q2 2026 | -$0.26 | -$0.06 |
| Q1 2026 | -$0.17 | +$0.26 |
| Q4 2025 | -$0.25 | -725% |
| Q3 2025 | -$0.17 | -$0.17 |
| Q2 2025 | -$0.20 | -195% |
| Q1 2025 | -$0.43 | -216% |
| Q4 2024 | $0.04 | -20% |
RDNT is still losing money, but less than at its worst: $0.28 per share over the past year, against $0.43 at its worst in early 2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RDNT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RDNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $638.3M | +22% |
| Q2 2026 | $622.7M | +25% |
| Q1 2026 | $575.6M | +22% |
| Q4 2025 | $547.7M | +15% |
| Q3 2025 | $522.9M | +13% |
| Q2 2025 | $498.2M | +8.4% |
| Q1 2025 | $471.4M | +9.2% |
| Q4 2024 | $477.1M | +13% |
RDNT's revenue has grown year over year every quarter since late 2020: $638M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.7% | -0.5 points |
| Q2 2026 | 6.3% | +0.1 points |
| Q1 2026 | -4.2% | +1 points |
| Q4 2025 | 5.1% | -0.1 points |
| Q3 2025 | 5.2% | -2.1 points |
| Q2 2025 | 6.2% | -1.4 points |
| Q1 2025 | -5.1% | -7.7 points |
| Q4 2024 | 5.1% | -0.7 points |
RDNT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RDNT on cash flow, with more consistent year-over-year improvement.
RDNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +$42.7M |
| Q2 2026 | $37.8M | -44% |
| Q1 2026 | $9M | +$16.4M |
| Q4 2025 | $33.1M | +$33.5M |
| Q3 2025 | -$7.6M | -147% |
| Q2 2025 | $67.4M | -2.8% |
| Q1 2025 | -$7.4M | +$33M |
| Q4 2024 | -$377K | -101% |
RDNT generated $115M in free cash flow over the past year, up 121% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RDNT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RDNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +443K shares |
| 1 year | +2.3% | +1.8M shares |
| 3 years | +15% | +10.4M shares |
| 5 years | +47% | +25.4M shares |
| Available history | +57% | +28.9M shares |
RDNT has 79M diluted shares, up 2.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RDNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.1x | Healthy |
RDNT's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RDNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.3 | Neutral |
| Stochastic | 65.1 | Neutral |
RDNT's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RDNT PE vs Healthcare Sector
| Metric | RDNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDNT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RDNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 5.6% above |
| 20 week MA | $71.2 | 6.8% above |
| 50 week MA | $66.8 | 14% above |
| 100 week MA | $65.1 | 17% above |
| 200 week MA | $54.2 | 40% above |
RDNT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RDNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $18.7 | -5.8% |
| 2021 | $18.7 | $30.4 | +62% |
| 2022 | $30.4 | $18.9 | -38% |
| 2023 | $18.9 | $34.8 | +84% |
| 2024 | $34.8 | $71.3 | +105% |
| 2025 | $71.3 | $73.2 | +2.6% |
| 2026 YTD | $73.2 | $76.0 | +4% |
RDNT has the edge over HIMS on returns for 2026, with the stronger performance.